A case to answer
Every now and again something intriguing comes along, which generates a flurry of interest from our readers in terms of early stage pipeline developments.
This example is no exception to the rule, judging from the enthusiastic questions we’ve received over the last couple of months.
Wit a raft of new clinical data available there’s a clear opportunity to explore exactly what’s what and is there something special coming along or is there a real risk/worry this might turn out rather like the IDO pathway with mixed red and green signals floating around?
The only problem here is after carefully reviewing all the evidence I found myself firmly in the sceptics/bear camp, at least for now.
It’s time to walk you all through what we found and what it all means…
To learn more about some ASCO GU21 and other recent data to get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
